Latest Philadelphia chromosome Stories
MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL.
U.S. and British scientists say they've identified a class of drugs that may enhance the effectiveness of medications used to treat chronic myeloid leukemia. People with chronic myeloid leukemia are usually first treated with a drug known as imatinib mesylate.
CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia.
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective.
EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
EAST HANOVER, N.J., Aug.
ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that it has submitted the non-clinical section of the rolling submission of a New Drug Application (NDA) for omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) to the U.S. Food and Drug Administration (FDA).
Exelixis has reported preliminary Phase I data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib.
ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs).
- An armed gangster.